Cleveland Clinic’s long-range study looks to unlock biomarkers for brain ailments
The Cleveland Clinic is in the third year of a first-of-its-kind brain study that was launched in 2022. The aim of the study is to identify biomarkers for neurological disorders earlier and either slow the progression or stop the progression all together.
It's estimated that 1 in 6 people worldwide live with a neurological disorder—a broad term that can include Alzheimer's, epilepsy, multiple sclerosis, Parkinson's, and stroke among others.
The study is expected to last for 20 years. Currently, more than 3,500 people from 46 states including Northeast Ohio are taking part in the study. But…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.